key: cord-0301265-0xllyo3p authors: Pratama, N. R.; Wafa, I. A.; Budi, D. S.; Putra, M.; Wardhana, M. P.; Wungu, C. D. K. title: Covid-19 Vaccination in Pregnancy: A Systematic Review date: 2021-07-06 journal: nan DOI: 10.1101/2021.07.04.21259985 sha: c3075eee2746dc22af7a63c96ca263c81ac34e5b doc_id: 301265 cord_uid: 0xllyo3p Objective: Pregnancy is a risk factor for severe Covid-19. Looking for safe vaccines that evoke protective maternal and fetal antibody response is important. Methods: We searched from registries (ClinicalTrials.gov, the WHO Clinical Trial Registry, and the EU Clinical Trial Registry) and databases (MEDLINE, ScienceDirect, Cochrane Library, Proquest, and Springer) up until June 20, 2021. Articles were selected based on inclusion and exclusion criteria after duplicates were removed. Infection rate, maternal antibody response, placental antibody transfer, and adverse events were described. This systematic review was performed with quality assessment and semi-quantitative synthesis according to PRISMA guidelines. Results: Twelve observational studies with a total of 40.509 pregnant women included. The mRNA based vaccines (Pfizer-BioNTech and Moderna) can prevent future SARS-CoV-2 infections (p=0.0004). Both vaccines did not affect pregnancy, delivery, and neonatal outcomes. The most commonly encountered adverse reactions are injection-site pain, fatigue, and headache but only transient. Antibody responses were rapid after the prime dose of vaccines. After booster, antibody responses were higher and associated with better placental antibody transfer. Longer intervals between first vaccination dose and delivery were also associated with higher antibody fetal IgG and better antibody transfer ratio. Conclusions: The Pfizer-BioNTech and Moderna vaccines are efficacious for preventing future SARS-CoV-2 infections. These vaccines can be considered as a safe option for pregnancy and their fetus. Two doses of vaccines were recommended for more robust maternal and fetal antibody responses. Longer latency was associated with higher fetal antibody responses. were not included in any initial Covid-19 vaccine trials, resulting in data scarcity to guide 77 vaccine decision making in these populations. 4 A prior study revealed that most pregnant 78 women with Covid-19 admitted to the hospital were asymptomatic, which allows these 79 undetected patients to transmit the virus to others. 5, 6 This finding shows that efforts to prevent women who received unknown types of vaccine. 18 Some studies compared vaccinated 158 pregnant women with unvaccinated pregnant women, either naturally infected or not infected, 159 or vaccinated non-pregnant women. The efficacy outcome was desribed as infection rate, 160 while immunogenicity was described as maternal antibody response, fetal antibody response, 161 and transplacental antibody transfer. Safety outcome was described as the adverse events, 162 maternal outcomes, and neonatal outcomes. Adverse events were divided into local and 163 systemic, local adverse events include injection-site pain and soreness, while systemic 164 adverse events include fatigue, headache, myalgia, chills, fever and nausea. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021 . ; 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 Reports not retrieved (n = 40) Reports assessed for eligibility (n = 42) Reports excluded (n = 32), due to: Review article (n = 9) Commentary / editorial (n = 18) Correspondence (n = 3) Animal study (n = 1) Opinion (n = 1) Records identified from: MedRxiv (n = 168) BioRxiv (n = 22) Clinicaltrial.gov (n = 9) Reports assessed for eligibility (n = 5) Reports excluded (n = 3), due to: Same study (n = 1) Non-pregnant population (n = 2) Studies included in systematic review (n = 12) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. After infection: A gradual rise in IgG humoral response (Anti-S1, S2, RBD and N) was detected during the first 45 days after infection. After the first dose: In the same period, vaccinated participants receiving the first BNT162b2 dose showed a rapid IgG response to S1, S2, RBD but not N, resulting in high titer values by day 15 after the first dose. After the second dose: A further rise in IgG was observed following the second dose. After the first dose: The temporal dependence of fetal IgG for S1, S2 and RBD after vaccination trailed after the maternal IgG showing a significant response already by day 15. After the second dose: A further increase was observed following the second vaccination dose. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. Two different case report studies from mother who received two doses of BNT162b2 vaccine Maternal outcomes were described as pregnancy outcomes and delivery outcomes. Compared to 286 unvaccinated pregnancy, vaccination did not significantly affect pregnancy or delivery outcomes. The adverse outcome index between vaccinated and unvaccinated pregnancy was insignificant 288 (p=0.9524). Between these group, there were no statistical difference in pregnancy outcome such as 289 eclampsia/pre-eclampsia (p=1), gestational hypertension (p=0.6038), gestational age (p=0.7028), 290 and thromboembolism incidence (p=1). 19 Moreover, the abortion rate was reported at 12.6% 291 (104/827) and 9.4% (60/636) had preterm birth. Statistically, vaccination also did not affect delivery 292 outcomes such as birth trauma (p=1), uterine rupture (p=1), unplanned ICU admission (p=0.1956), CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; As many as 15% (2/13) required NICU admission, 8% (1/13) experienced TTN, and 8% (1/13) 297 required supplemental oxygen or CPAP. Preterm delivery was reported in 8% (1/13) of women. 11 298 Moreover, 0.1% (1/725) were stillbirth, 3.2% (23/724) had small size for gestational age and 2.2% Maternal antibody response has been described formed following vaccination. [11] [12] [13] [14] [15] 17, 18, 20 317 Through vaccination, antibody response was formed rapidly; while through vaccination it was 318 formed gradually. 20 The number of IgG and IgM against SARS-CoV-2 were significantly increased 319 after vaccination. The response was increased after a booster was given. 11, 13 Although vast majority 320 of pregnant women had IgG seroconversion, IgM seroconversions were observed in a minority of 321 pregnant women. 18 After vaccination, IgG against S1, S2 and RBD formed whilst IgG against S1, 322 S2, RBD and N protein formed following natural infections. Moreover, S1-and RBD-IgG were 323 observed higher in vaccinated pregnant women. Meanwhile the S2-and N-IgG were observed 324 higher in naturally infected pregnant women. 20 Also, the RBD IgG and neutralizing antibody was 325 higher in vaccinated individuals than that of naturally infected. 12 Antibody transfer was also reported. 12, 14, 15, 17, 18, 20, 21 Cord blood antibody and maternal antibody 327 levels were about equal. 18 Additionally, latency and number of doses were correlated with the 328 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 6, 2021. ; antibody transfer strength. 14,18 The longer the latency, the better the antibody transfer and the higher 329 the IgG. 18 it was said that for a vaccine with 100% efficacy and providing life-long protection, we would need 336 60-75% herd immunity. This required number would be increased if the vaccine efficacy was 337 reduced to 85%; a 75-90% herd immunity would be required. 26 Although we described that Pfizer- During pregnancy, the upper respiratory tract was swollen and lung expansion was restricted. It 364 makes pregnant women more susceptible to respiratory pathogens. 33 Moreover, pro-inflammatory 365 phase was present in the first trimester, for the implantation of the embryo and placenta, and third 366 trimester, to prepare for the initiation of labor. 34 In fact, severe Covid-19 is associated with cytokine 367 storms. 35 The pro-inflammatory phase during the first and third trimester of pregnancy, made them 368 to be more prone to severe Covid-19. 36 Individuals with significant medical comorbidities, the elderly, and pregnant women are highly 370 vulnerable to Covid-19 infection. 37, 38 Although newborns and infants are less likely to get SARS- CoV-2 infections, they are more prone to severe SARS-CoV-2 infection. 37, 39, 40 Passive immunity in 372 neonates may be potentially protective. Administration of booster doses can enhance antibody 373 transfer which may provide a better immunity in neonates. However, this fetal passive immunity 374 may be altered due to placental sieving 41 , depending on the gestational age at first vaccine dose or vaccine was observed to have a more frequent systemic adverse events. Biologically speaking, we 412 may conclude that for a short term, vaccination did not affect pregnancy, delivery, or neonatal 413 outcomes. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 6, 2021. ; Coronavirus disease 2019 416 (COVID-19) pandemic and pregnancy Clinical features of patients infected with 419 2019 novel coronavirus in Wuhan Update: 422 Characteristics of Symptomatic Women of Reproductive Age with Laboratory SARS-CoV-2 Infection by Pregnancy Status -United States Coronavirus disease 427 2019 vaccine response in pregnant and lactating women: a cohort study Universal Screening for SARS-CoV-2 in Women 430 Admitted for Delivery Proportion of asymptomatic infection among COVID-19 positive persons and their 434 transmission potential: A systematic review and meta-analysis The 437 PRISMA 2020 statement: an updated guideline for reporting systematic reviews Coronavirus disease 448 2019 vaccine response in pregnant and lactating women: a cohort study COVID-19 mRNA Vaccines in Pregnant and Lactating Women SARS-CoV-2) Vaccination in Pregnancy: Measures of 455 Immunity and Placental Histopathology CoV-2 mRNA vaccines in pregnant women and their neonates. bioRxiv (preprint) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 461 Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy Adverse 464 effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional 465 study on healthcare workers with detailed self-reported symptoms Efficient 468 maternofetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after antenatal 469 SARS-CoV-2 BNT162b2 mRNA vaccination Cord blood antibodies following 472 22 Is Herd Immunity Against SARS-CoV-2 a 484 Silver Lining ? How to Understand COVID-19 Pandemic Does education about 489 local vaccination rates and the importance of herd immunity change US parents' concern about 490 measles? Challenges in creating herd immunity to SARS-492 CoV-2 infection by mass vaccination Vaccine epidemiology: A review Mounting a Good Offense against Measles Efficacy and Safety of 499 the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy 502 of the BNT162b2 mRNA Covid-19 Vaccine COVID-19 vaccine acceptance among pregnant women and mothers of young children: results 506 The unique immunological and microbial aspects of pregnancy Clinical features of patients infected with 2019 novel coronavirus in Wuhan Update: 519 Characteristics of Symptomatic Women of Reproductive Age with Laboratory SARS-CoV-2 Infection by Pregnancy Status -United States Assessing 523 the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, 524 and public policy implications Risk factors of critical & mortal COVID-527 19 cases: A systematic literature review and meta-analysis SARS-COV-2 530 infection in children and newborns: a systematic review Epidemiology of COVID-19 Among 533 Children in China Regulation of Placental Antibody Transfer CoV-2-specific placental antibody transfer Dengue 548 infection during pregnancy and transplacental antibody transfer in Thai mothers Transplacental 551 transfer of measles and total IgG Maternally derived 554 antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin 555 in preterm and full term newborns Safety and 558 immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during 559 pregnancy in mothers and infants: a randomized clinical trial SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Effects of SARS-CoV-2 variants on 565 vaccine efficacy and response strategies Emerging SARS-CoV-2 Variants and Impact in Global 568 Vaccination Programs against SARS-CoV-2/COVID-19 Novel SARS-CoV-2 variants: the 571 pandemics within the pandemic. Clinical Microbiology and Infection